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compared to normal saline infusion, with some possibilities of publication bias. 18, 19 However, other recent studies did not show a benefit of sodium bicarbonate. 15,16,20, 21 Furthermore, none of the previous meta-analyses detected evidence of potential harm, although parameters such as acid-base or electrolyte changes were not formally analyzed. We therefore conducted a systematic review and meta-analysis of published randomized controlled trials (RCTs) to determine the effects of sodium bicarbonate in preventing CI-AKI among patients undergoing diagnostic catheterization and interventional procedures. We also assessed differences in the requirement for dialysis, postprocedural death, and changes in serum acid-base and electrolyte levels.
Methods

Data Sources and Searches
We identified relevant studies through electronic searches of MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 2001 through January, 31 2012. Medical subject headings and keyword searches included the terms 'contrast nephropathy', 'sodium bicarbonate', 'sodium chloride', 'saline', 'renal failure', and 'radiocontrast'. Reference lists of selected articles were reviewed for other potentially relevant citations.
Study Selection
Two investigators (J.-S.J. and Y.H.P.) independently conducted the literature search, data extraction, and quality assessment by using a standardized approach. Selected publications were reviewed by the same investigators to assess if studies met the inclusion criteria: comparison of sodium bicarbonate vs. normal saline infusion, RCT. Final inclusion of studies was based on the agreement of both reviewers.
Data Extraction and Quality Assessment
Two reviewers (J.-S.J. and K.-I.C.) extracted relevant information from the articles including patient characteristics (mean age, sex distribution, risk factors, cardiac function); type of imaging; hydration protocol; serum creatinine level after radiocontrast administration; and data on primary (development of CI-AKI) and secondary outcomes (mortality, dialysis requirement, acid-base and electrolyte changes).
The definition of CI-AKI differed according to the study's protocol, but most described it as an absolute or relative increase in serum creatinine. Four studies defined CI-AKI as a rise in serum creatinine more than 25% within 2-5 days of contrast exposure, 11,22-24 whereas 2 studies defined it as an absolute increase of creatinine of 0.5 mg/dl or 0.3 mg/dl. 21, 25 Eleven authors used a combination of a 0.5 mg/dl absolute creatinine increase or a relative increase of 25%. 12-17,20,26-29 One study regarded an absolute increase of creatinine of 1.5 mg/dl or 25% relative decrease of estimated glomerular filtration rate (eGFR) 30 and Brar et al 31 used a change in GFR as the primary endpoint and a change in creatinine as a secondary definition of CI-AKI.
Data Synthesis and Analysis
Data on the results were collected on an "intention-to-treat" basis. We used odds ratio (OR) with 95% confidence interval (CI) to express dichotomous data. Continuous data were expressed as mean (SD) and weighted mean difference (WMD). The data from various studies were pooled and expressed as pooled OR or WMD with 95% CI. The pooled effects were calculated using either a fixed-effects model (Mantel-Haenszel method) or a random effects model (Dersimonian and Laird method). If no significant statistical heterogeneity was identified, the fixed-effects estimate was used preferentially as the summary measure. All P-values were 2-tailed, with statistical NaHCO3, 20 ml 5 min before procedure; NaCl, 1 ml · kg -1 · h -1 , for 12 h before and after procedure Increase of sCr >25% or 0.5 mg/dl within 3 days NaHCO3 better 1.6 mg/dl Iodixanol, a nonionic, iso-isomolar contrast medium NaHCO3, 3 ml · kg -1 · h -1 , for 1 h before and 1 ml · kg -1 · h -1 for 6 h after procedure; NaCl, 1 ml · kg -1 · h -1 , for 12 h after contrast infusion
Increase of sCr ≥25% within 5 days
No difference 1.3 mg/dl Iopamiron, nonionic, low-osmolar contrast medium 0.5 ml/kg as soon as possible, 1 ml · kg -1 · h -1 for 6 h after procedure
Increase of sCr >0.5 mg/dl or 25% within 2 days NaHCO3 better 1.7 mg/dl Iodixanol, a nonionic, iso-osmolar contrast medium NaHCO3, 3 ml · kg -1 · h -1 for 1 h before and 3 ml · kg -1 · h -1 for 6 h after procedure; NaCl, 1 ml · kg -1 · h -1 for 12 h before and after procedure Increase of sCr >25% or 0.5 mg/dl within 2 days
No difference 1.6 mg/dl Iohexol, a nonionic, low-osmolar contrast medium 3 ml · kg -1 · h -1 for 1 h before and 1 ml · kg -1 · h -1 for 6 h after procedure Increase of sCr >25% or 0.5 mg/dl within 5 days
No difference 1.6 mg/dl Iopamidol, a nonionic, low-osmolar contrast medium NaHCO3, NaCl 1 ml · kg -1 · h -1 before and after procedure, NaHCO3 1 ml · kg -1 · h -1 3 h before and 6 h after procedure; NaCl, 1 ml · kg -1 · h -1 before and after procedure Increase of sCr >25% or 0.5 mg/dl within 5 days NaHCO3 better 1.6 mg/dl Iodixanol, iopamidol, or ioversol, nonionic, low-osmolar contrast medium NaHCO3, 3 ml · kg -1 · h -1 for 1 h before and 3 ml · kg -1 · h -1 for 6 h after procedure; NaCl, 1 ml · kg -1 · h -1 for 12 h before and after procedure Increase of sCr >25% or 0.5 mg/dl at 2 days
No difference 137 μmol/L* 20 patients, nonionic, iso-osmolar contrast medium, all other patients, nonionic low-osmolar contrast medium NaHCO3, 3 ml · kg -1 · h -1 for 1 h before and 1 ml · kg -1 · h -1 for 6 h after; NaCl, 1 ml · kg -1 · h -1 from 8 p.m. and 12 h after procedure Increase of sCr >25% or 0.5 mg/dl at 2 days within 2 days NaCl better Sodium Bicarbonate for CI-AKI significance set at 0.05. To assess the effect of individual studies on the summary estimate of effect, we did an influence analysis, in which the pooled estimates were recalculated omitting one study at a time.
Heterogeneity across the included studies was analyzed using heterogeneity χ2 (Cochrane Q) statistic and I 2 test. I 2 values greater than 25%, 50%, and 75% were considered evidence of low, moderate, and severe statistical heterogeneity, respectively. 32 Publication bias was explored through visual inspection of funnel plot and confirmed by means of Egger's test (P for OR, odds ratio; and CI, confidence interval. JANG JS et al.
significant asymmetry <0.1). 33 Correction for publication bias was performed using the trim-and-fill method. Stratified analysis was performed to assess the effect of sodium bicarbonate-based hydration in selected patients groups (patients treated with low-osmolar vs. iso-osmolar contrast medium, and those undergoing elective vs. emergency procedures, article published before vs. after 2009, follow-up time before vs. after 48 h, and continuous vs. bolus injection of sodium bicarbonate administration). We also performed sensitivity analysis based on the presence of baseline renal dysfunction. All statistical analyses were performed using the Review Manager version 5.1 (The Nordic Cochrane Center, Copenhagen, Denmark) and MIX version 2.0 (BiostatXL, Sunnyvale, CA, USA). 
Results
A total of 416 articles were reviewed and 56 studies were selected for inclusion and further evaluated. Subsequently, 19 papers were included in the final analysis (Figure 1) .
A detailed description of the baseline characteristics of the included trials is given in Table 1 . Most studies were of patients who underwent coronary angiography or intervention via the intra-arterial route. Five studies also included patients who received contrast for peripheral angiographic or interventional procedures. 15-17,22, 23 The sodium bicarbonate hydration regimen as originally described by Merten et al 22 was used in all but 5 studies. 13,14,20,25, 26 The "Merten protocol" consists of the administration of 3 ml · kg -1 · h -1 of sodium bicarbonate in a glucose solution containing 154 mmol/L of sodium bicarbonate during the first hour preceding the contrast procedure, followed by infusion at a rate of 1 ml · kg -1 · h -1 for 6 h.
Primary Outcome
CI-AKI occurred in a total of 135 patients in the 1,810 patients of the sodium bicarbonate arms compared with 202 events in the 1,799 patients treated with normal saline. The summary OR was 0.56 (95% CI 0.36-0.86; P=0.008) in favor of sodium bicarbonate. Moderate statistical heterogeneity was noted among the included trials (heterogeneity χ2 =42.92; I 2 =58%; P=0.008; Figure 2) .
Stratified analyses suggested a more pronounced effect of sodium bicarbonate in studies using low-osmolar contrast media (OR 0.40; 95% CI 0. 23 The OR for the development of CI-AKI for sodium bicarbonate vs. normal saline among patients without pre-existing renal failure 25 was 0.07 (95% CI 0.01-0.52; P=0.007). The sensitivity analysis of the risk of CI-AKI in remaining 18 trials that enrolled patients with pre-existing renal failure yielded effect sizes with sodium bicarbonate (OR 0.61; 95% CI 0.40-0.92; P=0.02) that were similar to the overall results ( Table 2) . Among patients included in 2 studies using N-acetylcysteine (NAC) in addition to sodium bicarbonate and normal saline, 23,25 those who received NAC with sodium bicarbonate were associated with a lower incidence of CI-AKI (OR 0.12; 95% CI 0.04-0.42; P<0.001) ( Table 2) .
The cumulative analysis illustrates the time-course of the OR when performing a meta-analysis after each new study in chronologic order (Figure 3) . The ORs increase over time, illustrating early trials found more dramatic reduction in CI-AKI than later trials that have shown somewhat modest effects. None of the studies influenced the results to an extent that the conclusion would have changed: the sensitivity analysis of the risk of CI-AKI with sodium bicarbonate after exclusion of one study at a time yielded effect sizes similar in magnitude and direction to the overall estimates.
Assessment of publication bias using a funnel plot indicated slight asymmetry (Figure 4) and this was confirmed on formal testing (Egger's regression test intercept of −1.57; 95% CI of −3.137 to 0.003; P=0.05). However, the trim-and-fill method indicated that no missing studies were needed to achieve a symmetrical funnel plot.
Secondary Endpoints
Dialysis Requirement The need for dialysis was reported in 16 of the trials (n=2,835). Seven trials reported that none of the patients was actually treated with dialysis ( Figure 5A). 11-14,22,24,30 Overall, 14 among 1,425 patients treated with sodium bicarbonate underwent dialysis compared with 15 among 1,410 patients treated with saline. There was no statistical significance (OR 0.94, 95% CI 0.46−1.91; P=0.56).
Mortality In-hospital mortality was reported in 11 studies (n=2,349). In 6 of them, no deaths occurred in either group ( Figure 5B). 12,13,15,16,29,30 A total of 10 deaths occurred among the 1,175 patients treated with sodium bicarbonate and 20 deaths among the 1,174 patients treated with normal saline. There was a trend toward lower mortality risk in the sodium bicarbonate group compared to the normal saline group (OR 0.49; 95% CI 0.23−1.04; P=0.06).
Acid-Base and Electrolyte Changes Change in serum bicarbonate level after administration of sodium bicarbonate or normal saline was analyzed in 5 of the trials (Figure 6A). 13,15,17,22,27 The pooled effects showed a significant increase in serum bicarbonate level after sodium bicarbonate infusion compared with normal saline infusion (WMD, 2.63; 95% CI 1.72−3.55; P<0.001). Similarly, a change in serum potassium level was reported in 3 trials (Figure 6B). 13,15,22 Sodium bicarbonate infusion was associated with a significant decrease in serum potassium level when compared with normal saline infusion (WMD, −0.09; 95% CI −0.17 to −0.01; P=0.03).
Discussion
In the present meta-analysis, we found a lower incidence of CI-AKI with sodium bicarbonate-based hydration than with Figure 6 . Forest plots of odds ratios for change in (A) serum bicarbonate level and (B) serum potassium level. Sodium Bicarbonate for CI-AKI normal saline-based hydration. The beneficial effect of sodium bicarbonate was consistent across trials that included patients who had renal dysfunction at baseline and underwent elective or emergency angiographic procedures with contrast medium. A more pronounced effect of sodium bicarbonate was found in trials using low-osmolar contrast medium compared with those using the iso-osmolar agents. Greater estimates of effects were reported in studies that were published before 2009 and in studies with bolus injection of sodium bicarbonate. However, we could not find a significant benefit for the risk of death or requirement for dialysis following the administration of sodium bicarbonate over normal saline. In addition, we observed significant changes in serum bicarbonate and potassium levels after sodium bicarbonate infusion.
Although CI-AKI is generally regarded as a transient decline in renal function after contrast procedures, it cannot be regarded as a benign complication. In a study of patients undergoing contrast procedures, 0.8% of patients started dialysis and 13% of them required permanent dialysis. 1 The rate of dialysis was even higher in patients with diabetes and severe renal failure. 34 Also, it prolongs hospital stay, increases the medical costs 20 and portends a high morbidity and increased risk of in-hospital and long-term mortality. [35] [36] [37] [38] Several studies have shown that a mild, acute deterioration of renal function results in increased length of hospital stay, increased occurrence of CKD, increased death rates, and increased healthcare costs. 39- 43 The exact pathophysiologic mechanisms of CI-AKI are not fully understood, but possible explanations have been considered. Ischemic or oxidative injury to the kidney by contrast agent administration likely contributes to the development of CI-AKI. 44-46 Experimental studies have reported that contrast agents cause direct toxicity to the kidney through proximal cell vacuolization, interstitial inflammation, and cellular necrosis. 10, 45 Hemodynamic instability and low blood pressure secondary to underlying cardiac disease and the use of medications such as diuretics and renin-angiotensin system blockers could worsen CI-AKI. 47 Sodium bicarbonate decreases the acidification of urine and renal medulla, which might reduce the generation of free radicals and protect the kidney from injury 9,48,49 and thus prevent CI-AKI. After the initial report by Merten et al on the protective effect of sodium bicarbonate-based hydration on the incidence of CI-AKI, 22 several similar trials were performed. Although previous systematic reviews and meta-analyses of RCTs suggested an overall benefit of bicarbonate in reducing the incidence of CI-AKI, clinical endpoints such as renal replacement therapy, heart failure, and mortality were not improved. 19,50,51 Furthermore, predominantly underpowered trials of low quality with significant heterogeneity were pooled and there was evidence of publication bias. We included 19 such trials, and the cumulative result showed a beneficial effect of sodium bicarbonate in the prevention of CI-AKI in comparison to normal saline-based hydration. The results of the present study correspond with those of the previous meta-analyses. 19,51 However, we tried to further analyze changes in acid-base status and electrolyte level after sodium bicarbonate infusion and we found some evidence of potential harm following sodium bicarbonate infusion compared with normal saline. In contrast to previous meta-analyses where unpublished data were analyzed together, 19,50,52 we included only published randomized trials in our meta-analysis.
However, potential causes of heterogeneity should be considered in this meta-analysis, because the study populations and the study settings were varied. Stratified analysis revealed differences between sodium bicarbonate effects in emergency and non-emergency cases as a potential reason for the heterogeneity. In the setting of emergency PCI, low cardiac output, profound hypotension, as well as dehydration secondary to vomiting and diaphoresis, could contribute to prerenal azotemia. The exact mechanism by which sodium bicarbonate-based hydration results in a decreased incidence of CI-AKI in the emergency situation remains unclear. However, volume expansion with sodium bicarbonate infusion could stimulate dilution of circulating contrast medium and vasoconstrictive mediators and prevent activation of tubuloglomerular feedback more than normal saline hydration. 53 Similarly, sodium bicarbonate was less beneficial in patients who received iso-osmolar contrast medium than in those who received low-osmolar contrast agents. 54, 55 Earlier studies suggested that nonionic, isoosmolar contrast medium may be less nephrotoxic compared with low-osmolar contrast agents. However, more recent studies have failed to show any statistical difference in the incidence of CI-AKI after the administration of iodixanol or lowosmolar contrast media to high-risk patients. 56- 58 Reed et al conducted a meta-analysis of RCTs of 16 trials including 2,763 patients and found no significant differences in the incidence of CI-AKI, rates of postprocedural dialysis or death. 59 The mechanism responsible for the more pronounced effect of sodium bicarbonate in patients receiving low-osmolar contrast media in our meta-analysis is difficult to elucidate because of the small number of included studies and no adjusted comparison of variable clinical conditions. However, we could assume that the beneficial effect of sodium bicarbonate might be offset by iso-osmolar contrast agents, which have a more physiologic profile in terms of renal hemodynamics. 60 Cumulative analysis of the included studies further supports the conclusion that, at no particular time point since 2004, 22 the OR pointed towards an inferiority of sodium bicarbonate. It shows that the effect of sodium bicarbonate was significantly overestimated initially and the inclusion of later studies with more narrow CIs suggesting greater reliability of the effect estimate.
Although prophylactic administration of NAC is known to decrease the incidence of CI-AKI 61 and a meta-analysis demonstrated that the combination of NAC and sodium bicarbonate is significantly better than each individual regimen in preventing CI-AKI, 62 the definitive role of NAC is not yet established. Furthermore, the Acetylcysteine for Contrast-Induced Nephropathy (ACT) trial 63 showed that short-term use of high-dose NAC does not reduce rates of CI-AKI or a combined endpoint of mortality or the need for dialysis at 30 days in at-risk patients undergoing coronary or peripheral vascular angiography. The Renal Insufficiency Following Contrast Media Administration (REMEDIAL II) trial 64 reported that RenalGuard therapy (hydration with normal saline plus high doses of NAC with a limited (0.25 mg/kg) dose of furosemide controlled by the RenalGuard system) is superior to the combination of sodium bicarbonate and NAC in preventing CI-AKI in high-risk patients. In our meta-analysis, the benefit of sodium bicarbonate among those prescribed NAC was demonstrated in a stratified analysis. The incidence of CI-AKI was significantly reduced among those who received sodium bicarbonate and NAC compared to those who received normal saline and NAC. Appropriately designed, large-scale randomized clinical trials are required to determine whether sodium bicarbonate in combination with NAC is more effective in preventing CI-AKI than sodium bicarbonate alone or NAC alone.
In the present study, we did not find a difference in terms of dialysis requirement and mortality, and this could be attributed to the lack of power of the included studies. The sample size of each trial is relatively small and the studies were not JANG JS et al.
designed and powered to detect mortality differences following sodium bicarbonate-based and normal saline-based hydration.
Study Limitations
First, in our meta-analysis, the included trials were of short duration and not adequately powered to measure patient-centered outcomes such as dialysis requirement and death. Second, the number of patients, the inclusion and exclusion criteria, and the dose and duration of therapy with sodium bicarbonate varied across the trials. Third, we did not have access to patientlevel data to determine whether preexisting decreased renal function and other risk factors (eg, diabetes and advanced age) could influence the effect of a bicarbonate-based regimen on the risk of CI-AKI. Fourth, most studies included in this study showed the efficacy of sodium bicarbonate in patients undergoing coronary procedures. Therefore, it may be difficult to generalize these results to patients undergoing non-coronary diagnostic or interventional procedures using intravenous contrast. Fifth, 13 trials included in our study defined CI-AKI as a rise in serum creatinine within 48 h after contrast exposure. Because creatinine typically rises 4-5 days after contrast use, the effect of sodium bicarbonate might have been exaggerated in studies that measured primary outcome within 2 days.
Conclusions
Our meta-analysis suggests that the use of bicarbonate-based hydration in comparison to normal saline significantly reduces the incidence of CI-AKI, although the magnitude of the benefit may have been overestimated by earlier studies. The use of sodium bicarbonate, however, did not result in significant benefit in terms of a reduction in deaths or the requirement for dialysis. Also, we found significant changes in serum bicarbonate and potassium levels following sodium bicarbonate infusion, which can be hazardous for patients. Adequately powered trials that measure patient-oriented outcomes in participants with different individual risks of CI-AKI are needed. In addition, physician's should ensure that CI-AKI is avoided by conducting a preoperative evaluation of vascular disease with a small amount or no contrast media in patients with preexisting renal insufficiency. 65 However, the lack of any study demonstrating the superiority of saline-based prophylactic hydration suggests that a sodium bicarbonate-based regimen could be considered optimal hydration in high-risk patients undergoing exposure to iodinated contrast media.
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